Structure and Expression of RPL23A_15_676: A Potential Drug Target Or Biomarker

Target Name: RPL23AP1

NCBI ID: G6148

RPL23AP1

Other Name(s): RPL23A_15_676 | Ribosomal protein L23a pseudogene 1 | dJ377H14.8 | ribosomal protein L23a pseudogene 1

Structure and Expression of RPL23A_15_676: A Potential Drug Target Or Biomarker

RPL23A_15_676 is a protein that is expressed in various tissues of the body, including the brain, heart, and skeletal muscles. Its full name is Rabbit polyclonal 23A (RPL23A), and it is a member of the Rabbit polyclonal family 23. This protein is of interest as a potential drug target or biomarker due to its unique structure and expression pattern in various tissues of the body.

Structure

RPL23A_15_676 is a 21 kDa protein that consists of 15 transmembrane 伪-helices and 676 amino acid residues. It has a unique structure, with a N-terminal cytoplasmic domain, a transmembrane region, and a C-terminal T-loop domain. The N-terminal cytoplasmic domain is rich in conserved putative transmembrane interactions (TMIs), including a putative IP3 -dependent protein-protein interaction (PIP) domain and a putative G protein-coupled receptor (GPCR) domain. The transmembrane region is composed of an 伪-helix and 尾-sheet.

Expression

RPL23A_15_676 is expressed in various tissues of the body, including the brain, heart, and skeletal muscles. It is highly expressed in the brain, with higher levels of expression in the prefrontal cortical cortical region compared to other regions of the brain. It is also expressed in heart and skeletal muscles, with lower levels of expression compared to the brain.

Drug Targeting

RPL23A_15_676 is a potential drug target due to its unique structure and expression pattern. The N-terminal cytoplasmic domain is rich in conserved putative transmembrane interactions, including a putative IP3-dependent protein-protein interaction (PIP) domain and a putative G protein-coupled receptor (GPCR) domain. These domains suggest that RPL23A_15_676 may be involved in intracellular signaling pathways, including IP3 signaling and GPCR signaling.

Biomarker

RPL23A_15_676 may also be a biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. Its high expression in the brain suggests that it may be involved in brain function and development. Its expression in heart and skeletal muscles suggests that it may be involved in maintaining muscle mass and function.

Conclusion

RPL23A_15_676 is a unique protein that is expressed in various tissues of the body. Its unique structure and expression pattern make it a potential drug target or biomarker. Further research is needed to determine its role in intracellular signaling pathways and its potential as a drug target or biomarker.

Protein Name: Ribosomal Protein L23a Pseudogene 1

The "RPL23AP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets